22.1 Introduction

Emerging infectious diseases according to the CDC-hosted journal *Emerging Infectious Diseases* (www.cdc.gov/ncidod/EID/about/background.htm) are defined as diseases “whose incidence in humans has increased in the past two decades or that are expected to have an increased incidence in the near future.” These diseases respect no regional, national, or international boarders and include (1) new infections resulting from changes or evolution of existing organisms, (2) known infections spreading to new geographic areas or populations, (3) previously unrecognized infections appearing in areas undergoing ecologic transformation, (4) old infections re-emerging as a result of antimicrobial resistance, and, finally and most importantly for the field of virology, (5) infections caused by newly discovered agents.

After the discovery of the human metapneumovirus (hMPV) in 2001 and the 2002/2003 outbreak of severe acute respiratory syndrome (SARS), the number of known emerging viruses expanded at a fast pace, mainly due to the development of novel virus identification methods and their routine use in patients with suspected infections but negative findings from conventional diagnostic methods. This chapter focuses on these new pathogens and highlights their role in patients with hematological malignancies.

22.2 Human Metapneumovirus

In 2001 the hMPV was described as the third known *Paramyxovirinae* to cause disease in humans, together with the respiratory syncytial virus (RSV) and
parainfluenza viruses (PIVs), all of which cause respiratory infections [204]. Infections with hMPV and RSV occur worldwide and are associated with a broad clinical spectrum ranging from mild to life-threatening disease. Our group and others have shown that hMPV infections in hospitalized patients or in the elderly are at least as severe as RSV infections [125, 146, 147, 175, 178, 204–206, 218, 220, 221, 229]. Whether hMPV infections cause milder symptoms than RSV infections in otherwise healthy individuals has not yet been systematically investigated. Furthermore, hMPV and RSV often occur as co-pathogens and may then cross-react directly or indirectly [229].

Genetically, hMPV is most closely related to the avian metapneumovirus (APV) [204] and is assumed to have a zoonotic origin, a possibility supported by the fact that it can be transferred to APV-susceptible poultry. Serological and bioinformatic analyses indicate that passage to humans occurred more than 50 years ago [47, 48, 210].

In contrast to RSV, hMPV lacks two genes coding for the nonstructural proteins NS1 and NS2, both of which are assumed to interact with the host’s immune response. For this reason, RSV and hMPV may induce different host immune responses [25, 59, 122, 123, 144, 148, 191]. While RSV may be defined as a re-emerging pathogen, at least in some patient cohorts where it was previously underestimated [174], hMPV has been shown to cause a number of severe respiratory events in patients with hematological malignancies. RSV infection and hMPV infection are indistinguishable on clinical grounds alone [229].

In one study including 114 lung transplant recipients, hMPV was detected in bronchoalveolar lavage (BAL) fluid from about 5% of symptomatic patients [45]. Further cases were described after lung and heart–lung transplantation in patients having histological findings of acute pneumonia with diffuse alveolar damage and hyaline membrane formation [112, 192]. In hematopoietic stem-cell transplant recipients, hMPV can cause life-threatening disease. Englund and colleagues described a case series in which the hMPV detection rate by RT-PCR was about 26% among symptomatic patients, and 80% of hMPV-positive patients died from severe infection [63]. Furthermore, in stem-cell transplant recipients, viral shedding and persistence may be prolonged compared to otherwise healthy individuals and may be accompanied by severe infection characterized by rapidly progressive pneumonia with diffuse alveolar hemorrhage [50, 63]. Until now, ribavirin has been the only antiviral agent used to treat severe hMPV infections [28, 85, 93, 165]. Ribavirin was tested in a mouse model and used successfully in two published clinical cases. To date, no other antivirals or vaccines are available.

**22.3 Human Bocavirus**

Human bocavirus (HBoV) may be an emerging respiratory virus. It was first discovered in 2005 by the Swedish research group led by Tobias Allander at the Karolinska University Hospital in Stockholm [9]. The discovery was made possible by a novel molecular virus screening technique involving DNase treatment, random amplification, cloning, and sequencing. The newly found virus showed up as a possible cause of respiratory disease, particularly acute respiratory tract infections. Clinical symptoms include coughing, fever, and rhinorrhea. It is still unclear whether HBoV is able to trigger disease on its own or occurs only as a co-pathogen [176].

Comparisons of the genomic sequence to other known viruses suggest that HBoV may belong to the Parvoviridae family, Parvovirinae subfamily, and Bocavirus genus. This genus has two other viruses, namely, bovine parvovirus (BPV) and canine minute virus (CnMV). HBoV may be the second Parvoviridae known to cause human disease, after parvovirus B19, which belongs to the Erythrovirus genus. Several nonpathogenic parvoviruses are also known to infect humans, including the adeno-associated viruses (AAV) of the parvovirus family, Dependovirus genus, and, in the same family, parvovirus 4 (PARV4), a possible member of the Hokovirus genus [113]. Two new viruses classified as HBoV2 and HBoV3 were discovered recently. HBoV2 has 75% similarity to HBoV, compared to only 18% for HBoV3 and HBoV2 [12, 100]. HBoV2 was detected in children with acute gastroenteritis in England, Pakistan, and Australia, whereas HBoV3 was detected during the course of an HBoV2 surveillance program but could not be associated to any symptoms [12].

HBoV is a non-enveloped single-stranded DNA virus, encapsulated in a simple icosahedral shell with a diameter of 20–26 nm, made up by the arrangement of
two proteins. The main genome body containing the open reading frames (ORFs) encoding viral proteins has been sequenced and shown to be 5,309 nt in length [115]. The entire genome length is predicted to be about 6,000 nt [8, 9]. Experiments to directly sequence the virus genome failed and led to faulty data [9, 27]. HBoV is thought to have palindromic hairpin structures flanking the terminal ends, similar to related *Parvoviridae* (e.g., BPV and CnMV). The function of the terminal folds is not fully understood, but it is thought that they act as primers in viral replication and are important for packaging [101]. Until now, it was not possible to decipher the unknown sequences. Attempts to amplify the regions encoding specific enzymes did not reveal the nucleotide sequence [9]. An undetected protein covalent or other protein modification on the HBoV genome may explain this failure, as other parvoviruses (B19, MVM, and H1) possess protein covalents attached to their genomes [39, 51, 168]. Recent findings reveal that the majority (87.5%) of the ssDNA strands packed in the capsid are of negative polarity, independent from their viral subtypes [27].

The genomic composition is as yet unconfirmed, and so far three ORFs have been identified, similar to BPV and CnMV. One of these ORFs encodes for the viral capsid proteins VP1 and VP2, whereas the other two encode for non-structural proteins. The VP2 gene sequence is nested within the VP1 gene sequence. The VP1 sequence, compared to VP2, contains a unique terminal sequence, VP1u [163], which may be required for HBoV genome transfer to the nucleus for replication [236]. The HBoV capsid is composed of 60 proteins, derived from the structural molecule VP1 and its derivative VP2 [9]. The functions of the non-structural proteins NS1 and NP-1 are still equivocal. NS1 may play a role in replication. It generally acts as an initiator protein (for parvoviruses), specifically controlling the process by which several concatemeric intermediates are processed by rolling-hairpin replication [15]. The role for NP-1, located in the middle ORF, is still unclear, but probably also involves parvovirus replication. The transmission route of HBoV is still unknown, but suggested tissue sites for replication are the respiratory and intestinal epithelia, as well as the lymphatic organs. Parvoviruses replicate only in proliferating cells, and the viral proteins are transcribed only during the S-phase. Recently, an in vitro replication system for HBoV using stratified human airway epithelium to imitate the human trachea was successfully established.

The cells were inoculated with HBoV-positive material from respiratory tract secretions of hospitalized children. Apical HBoV release from the cells was confirmed using PCR. This study further showed that the transcription model resembled that of both of the other known bocaviruses (BPV and MVC) [52].

Symptoms associated with possible HBoV infection are wheezing, fever, bronchiolitis, and pneumonia [8, 12, 19, 31, 33, 41, 43, 44, 49, 97, 114, 118–121, 124, 126, 141, 176, 177, 179, 183, 195, 198, 203, 213, 219, 226, 235, 237, 239]. However, the presence of HBoV in the respiratory tract does not prove that the virus is the cause of infection. HBoV is often detected concomitantly with other respiratory viruses [41, 216, 226], a fact that adds to the uncertainty regarding the pathogenic potential for HBoV [41, 66, 91, 97, 118, 124, 128, 136, 176, 200, 203, 213, 217, 226, 239]. The symptoms are identical in patients positive for HBoV alone or combined with another virus, but the viral load is higher in mono-infections than in coinfections. Asymptomatic patients can carry the virus. In one study, 43% of tested asymptomatic children were HBoV-positive. These patients were admitted for elective surgery, and the group undergoing mainly ear, nose, and throat surgery had the highest prevalence of asymptomatic HBoV infection [124]. These data suggested that HBoV may persist in the host in the tonsillar lymphoid tissue, contributing to tonsillar hyperplasia [126]. HBoV has been detected in patients with symptoms of gastrointestinal infection, but it is unclear whether the virus is only excreted in stool or is a cause of gastroenteritis. In these studies, HBoV was found concomitantly with a norovirus or other enteric viruses, and HBoV was not directly proven to be a cause of gastrointestinal infection. The virus in suspension in respiratory secretions may be simply swallowed and excreted in stool. The newly discovered HBoV2 and HBoV3 have both been detected in stool samples. HBoV2 was identified in a study involving stool sample screening in children with non-polio acute flaccid paralysis [12, 100, 179], and HBoV2 and HBoV3 were detected in hospitalized children with acute gastroenteritis. More studies on the two new HBoV types are needed to gain a better understanding of their role in gastrointestinal infections. No evidence that HBoV2 and HBoV3 can infect gastrointestinal tissue exists to date. Furthermore, whether detection of these viruses in serum indicates viremia or infection of blood cells is unknown, because there are no currently established methods for detecting HBoV particles. The related parvovirus B19
can infect erythroid progenitor cells in the bone marrow, but no HBoV DNA was detected in bone marrow samples from human immunodeficiency virus (HIV)-positive and -negative individuals, whereas B19 was present in both groups [76, 146]. So far, there is one published report of HBoV associated with severe pneumonia in a pediatric hematopoietic stem cell transplant recipient [172, 173] and one of HBoV infection in an adult with leukemia [109]. However, none of these patients had clinical symptoms different from those caused by other “common cold” pathogens, and no specific antiviral therapy was available.

Since the discovery of HBoV, infections with this virus have been found worldwide. The prevalence of infections in which HBoV may be a causative factor ranges from 1.5% to 19.3%. No seasonal variations have been described. HBoV occurs mainly in pediatric patients aged 6–24 months [4, 5, 9, 10, 12, 16, 17, 37, 40, 42, 44, 61, 74, 77, 86, 91, 95, 99, 103, 116, 127, 132, 143, 149, 158, 160, 162, 166, 167, 179, 187, 189, 194, 214, 219, 226, 235, 238]. Younger children may be protected by maternal antibodies [38]. HBoV-IgG can cross the placental barrier, but it is unclear whether HBoV can be transmitted from the mother to her fetus. Antibodies against HBoV have been found in about 94% of individuals older than 19 years of age [44]. At the moment, only two different genotypes of the single HBoV lineage are known. A simple verification test is available for rapidly differentiating between these two genotypes. Digestion of a 309-bp fragment of the VP1/VP2 gene with BstAPI endonuclease yields two fragments with genotype 1, but induces no cleavage with genotype 2 [54]. Three HBoV2 genotypes have been identified [5], but no information is available for HBoV3.

Despite a large number of clinical studies, the biological background of HBoV is still unknown. The virus can be replicated in a cell line. However, complete genome sequencing is needed to fully understand the virus. As this virus may cause acute respiratory disease, it is crucial to understand the disease process and its causative agent.

22.4 Human Coronaviruses

As of August 2009, five human coronaviruses (CoVs) were known, of which three meet the definition of emerging pathogens. The five human CoVs are OC43 and 229E, two long-known viruses that cause respiratory and/or gastrointestinal disease, and the emerging viruses SARS-CoV [56], NL63 [207], and HKU-1 [233]. SARS-CoV appears to be an archetypical zoonosis responsible for a single outbreak, which was unfortunately accompanied with high mortality and had the potential for a pandemic event. The two other newly detected CoVs, NL63 and HKU-1, occur periodically and infect all age groups worldwide.

After the identification in the 1960s of the first CoVs known to cause human disease, HCoV-229E and HCoV-OC43, and their association with mild respiratory disease [30, 34, 67, 84, 137, 142], little new information emerged in this field until the beginning of the twenty-first century. In 2002/2003, a CoV appeared in the Guangdong province of China, causing severe acute respiratory syndrome (SARS) [56, 108, 156]. SARS was fatal in some patients, although at the time CoVs were believed to cause only mild disease. Strenuous efforts were made to identify and to characterize this new virus and to curb its potential for causing a pandemic.

Among the heterogeneous Coronaviridae family, CoV NL63 (HCoV-NL63) was identified in 2004 [207] and CoV HKU1 (HCoV-HKU1) in 2005 [232]. In contrast to SARS-CoV, these newly detected CoV led to clinical symptoms similar to those caused by HCoV-229E and HCoV-OC43. Considerable research has been undertaken to learn more about these viruses, their differences, similarities, and characteristics. This review focuses mainly on SARS-CoV and HCoV-NL63.

Several techniques were employed to characterize and to identify the agent causing SARS. Tests for known respiratory viruses were negative. Patient samples were inoculated onto Rhesus monkey kidney cells (fRhk4) to look for cytopathic effects. Electron microscopy revealed the morphology of the virus and led to characterization of the virus family. Histopathological studies showed mild interstitial inflammation with scattered alveolar pneumocytes. In an immunofluorescence antibody assay, sera from patients had high titers of antibodies against the infected cells. A random RT-PCR assay generated DNA fragments of unknown origin, but with homology to viruses of the Coronaviridae family, and confirmed the results of electron microscopy. A few days later, these results were confirmed by two other groups [56, 108, 156].
SARS and its causative agent appeared unexpectedly and spread explosively. The infection was transmitted from palm civets to humans, although it has since been confirmed that bats are the natural reservoir of SARS-CoV. Due to the fast mutation rate of RNA viruses and their resulting genotypic markers, the course of the infection could be reconstituted in great detail. In the early phase of the SARS near pandemic, the very first index patient fulfilling the subsequent WHO definition of SARS resided in Foshan near Guangzhou and was identified on November 16, 2002. One month later, the second case occurred, in Shenzhen, where a man who had regular contact with wild animals was infected and transmitted the disease to his family and to several staff members at the hospital where he was admitted. Similar cases were reported nearby. In January 2003, the second phase of the SARS outbreak started in Guangzhou. Several patients died, and patients were transferred to major hospitals, leading to nosocomial spread of the virus to other patients and health-care workers.

The next and final phase started in mid-February 2003 and heralded the pandemic. A doctor was infected in Guangdong province and took the disease to Hong Kong, where he stayed in a hotel ("hotel M"). He infected 17 other people, who were admitted to different hospitals, where further nosocomial infections occurred. Some of the infected patients transferred the virus via air travel to Vietnam, Singapore, and Toronto, where new cases emerged. A novel CoV was identified on March 21, 2003, and confirmed a few days later. The first strain (Tor2) was fully sequenced on April 12, 2003, and SARS-CoV was proven to be the cause of SARS [134]. In July 2003, the epidemic ended, with no further human-to-human transmissions being reported. In September 2003, a new case was reported at a laboratory in Singapore, and over the next 2 years other accidents occurred in laboratories.

HCoV-NL63 was discovered in a 7-month-old child with bronchiolitis. Diagnostic tests for all known respiratory viruses were negative. Inoculation of a sample on tMK and, later on, LLC-MK2 cell cultures produced a cytopathic effect. In the LLC-MK2 cell culture supernatant, a new virus was identified using the VIDISCA method [161, 207]. Sequence comparisons established that the virus was most closely related to HCoV-229E and, together with PEDV and Bat-CoV, belonged to the coronavirus subgroup 1b. Two further research groups obtained identical results soon afterward [65, 72].

There is some indication in the literature that HCoV-NL63 was detected much earlier. Viruses were described that did not exhibit all the characteristics of HCoV-229E or HCoV-OC43. Unfortunately, these isolates were lost, so that studies could not be done to determine whether one or more of them were identical to HCoV-NL63. SARS-CoV and HCoV-NL63 are both members of the Coronavirus genus, Coronaviridae family, within the Nidovirales order. Both organisms are positive single-stranded RNA viruses with a large genome of about 30 kb. The virus particles are enveloped and possess peculiar spike-shaped proteins on their surface that produce a crown-like appearance. Electron microscopy revealed particles of 80–140 nm located either within the infected cells at the rough endoplasmic reticulum in double-membraned vesicles or outside the cells attached to the plasma membrane.

The genomes of both SARS-CoV and HCoV-NL63 can be roughly divided into two parts. The 5′ two-thirds consists of one large polyprotein (ORF1ab) including several domains with autocatalytic activities, producing nonstructural proteins (NSPs) involved in replication and immune evasion. ORF1ab encodes 16 NSPs in toto in both SARS-CoV and HCoV-NL63.

The last third at the 3′ end of the genome contains the ORFs coding for the functional proteins – spike (S), envelope (E), membrane (M), and nucleocapsid (N) – and for accessory protein genes that vary in number and position across species.

Traditionally, CoVs were classified – due to their antigenic cross-reactivity – into three groups, which were largely confirmed later on by sequence analysis results. Group I and II viruses infect mammals, whereas group III viruses infect only birds. While HCoV-NL63 belongs to group 1b, SARS-CoV and the bat CoVs are considered group 2b viruses, although bat CoVs constitute a newly identified CoV group.

HCoV-NL63 is most closely related to HCoV-229E, and phylogenetic analysis findings suggest that HCoV-NL63 may have diverged from HCoV229E in the twenty-first century. Furthermore, there seem to be two main genetic clusters of HCoV-NL63, and there is evidence that the HCoV-NL63 genome is arranged in a mosaic-like manner.

Patients infected with HCoV-NL63 usually experience only mild symptoms, including cough, rhinitis, rhinorrhea, and pharyngitis, often with a fever. In rare cases, pneumonia can occur, chiefly in children aged 0–3 years, older people, and immunocompromised
individuals. Among children with severe lower respiratory tract infection, a substantial number have croup compared to a control group. Croup or laryngotracheobronchitis is characterized by a loud barking cough, inspiratory stridor, and hoarseness. An association with Kawasaki disease has been postulated but not confirmed despite studies by a number of research groups [11, 14, 15, 53, 58, 87, 106, 111, 140, 188, 190, 193, 202, 208].

After the detection of HCoV-NL63 in The Netherlands and, later on, in New Haven, CT, USA, this virus was found in a number of countries, suggesting a worldwide distribution. Except in subtropical regions, HCoV-NL63 was mainly detected in the winter months and often turned up with other co-pathogens, such as influenza, RSV, parainfluenza, and hMPV. The HCoV-NL63 load is attenuated when there is another pathogen. However, and not surprisingly, the infection itself seems more severe in co-infections. As with SARS-CoV, HCoV-NL63 is detectable up to 2 months after recovery from the disease. Seroprevalence studies showed that virtually every adult encounters HCoV-NL63 at least once in a lifetime. Antibodies specific for the S protein are produced and display a neutralizing effect.

People infected with SARS-CoV had a fever, chills, myalgia, rigor, and a nonproductive cough. Clinical symptoms such as rhinorrhea and sore throat were less common. In contrast to HCoV-NL63, SARS-CoV did not infect children, and the disease occurred instead in normal and healthy adults and in the elderly. Of 8,096 infected people, 774 died, demonstrating a nearly 10% mortality rate. SARS-CoV spread to more than 30 countries [26, 29, 35, 94, 186, 227]. The first outbreak occurred in late 2002/early 2003. Seasonality of HCoV-NL63 infection is not known, as the pandemic occurred only once, with the peak in winter. It has been confirmed that SARS-CoV is a zoonosis that originates primarily from bats. Although SARS-CoV was initially spread from civets to humans, the actual transmission route was from humans to humans, most likely by droplets, and probably occurred in health-care facilities, at workplaces, and when using public transportation. The virus was detected not only in the respiratory tract, but also in the gastrointestinal tract, liver, kidney, brain, and other tissues.

Seroprevalence was quite low among the general population, ranging across studies from 0% to 1.81% and being slightly higher in asymptomatic health-care workers. In contrast, a much higher rate (up to 40%) was found in asymptomatic animal handlers, which was not surprising, as these individuals probably acquired immunity via less pathogenic SARS-CoV-like strains that also emerged by zoonotic recombinations. SARS-CoV infection can be accompanied by co-pathogens such as other respiratory viruses (e.g., hMPV) or other CoVs.

The association of SARS-CoV with severe pneumonia in patients with hematological malignancies occurred only during the single outbreak, and studies on the role for NL63 in these high-risk patients are still limited. However, 229E has been detected in hematopoietic stem cell transplant recipients with high fever, cough, and interstitial and alveolar lung disease [157].

### 22.5 Polyomaviruses

Recently, two novel polyomaviruses were detected in respiratory aspirates. Allander et al. in Sweden discovered a previously unrecognized third human polyomavirus in 6 (1%) of 637 nasopharyngeal aspirates and 1 (0.5%) of 192 fecal samples, and suggested the name KI polyomavirus (KIPyV) [7]. The second newly identified polyomavirus was found by Gaynor et al. in respiratory samples from Brisbane, Australia, and St. Louis, MO, USA. This “Washington University” (WU) genome polyomavirus (WUPyV) was amplified and cloned from the nasopharyngeal aspirate of a 3-year-old patient with pneumonia and negative tests for other respiratory viruses. Screening of 2,135 patients with respiratory tract infections identified 43 additional cases [79]. Of note, KIPyV was not named for the Karolinska Institute in Stockholm where it was detected. Since the first description of KIPyV and WUPyV, a number of prevalence studies from various areas have been published, but the association of these viruses with acute respiratory tract infections remains unclear [2, 13, 117].

Prevalence studies of KIPyV and WUPyV showed a worldwide distribution. The prevalence of KIPyV was 1% in Sweden, 1.4% in the United Kingdom, 1.99% in Thailand, and 2.6% in Australia [7, 23, 152, 155]. The prevalence of WUPyV was higher, 7% in South Korea, and 6.29% in Thailand [88, 155]. Australia, the USA, and the UK had WUPyV prevalences of 4.5%, 1.2%,
and 1.0%, respectively [23, 79, 152]. The age distribution of KIPyV- and WUPyV-infected patients showed two peaks, in patients younger than 15 years (with the highest rates occurring before 5 years of age) and older than 45 years [3, 150]. Seasonal variations in KIPyV and WUPyV did not appear consistently. KIPyV infections predominated during the winter months in Thailand but not in Australia. In contrast, WUPyV infections were predominantly detected during late winter, peaking in December to early summer in Australia but not in Thailand [23, 24, 155].

KIPyV and WUPyV are frequently associated with other respiratory viruses. High co-detection rates were found in Australia, 74.7% for KIPyV and 79.7% for WUPyV, and the most commonly co-detected viruses were human rhinovirus and HBoV. Co-detection of KIPyV and WUPyV was found in 14 patients, of whom only 1 had no other respiratory virus [23]. Norja et al. detected KIPyV or WUPyV in 19 patients and found a viral coinfection rate of nearly 50% with predominant detection of adenoviruses. The overall frequencies of KIPyV and WUPyV detection were similar in patients with upper respiratory tract infection, lower respiratory tract infection, or no respiratory symptoms, and eight patients were immunosuppressed, although overall the patient groups were not very well described [152].

Data are not available to determine whether KIPyV and WUPyV detection represents a similar phenomenon to JCV and BKV reactivation in immunocompromised patients, or whether KIPyV and WUPyV share the oncogenic potential of other human and animal polyomaviruses, and further studies are needed [242]. However, Koch’s modified postulates have not been verified so far, and whether KIPyV and WUPyV are respiratory pathogens or innocent bystanders is still debated. Further studies are required to evaluate the clinical relevance of KIPyV and WUPyV detection in respiratory specimens.

Another newly recognized polyoma virus of interest may be the Merkel cell polyoma virus, MCPyV, recently identified in Merkel cell carcinoma. MCPyV may have oncogenic potential, as it is found mainly in lesional and non-lesional skin from patients with Merkel cell carcinoma and other skin diseases [73]. This oncogenic potential, as well as experience with other oncogenic viruses such as EBV, suggests a high likelihood of MCPyV generating clinical events in patients with hematological malignancies. However, until now, there are more questions than answers regarding this new virus. The role for MCPyV in disease is unclear, and cell-culture and animal models are not yet available [169].

### 22.6 Picornaviruses

Within the group of picornaviruses, two emerging virus lines were identified recently, namely, rhinovirus X associated with severe respiratory disease and the parechoviruses. The newly identified rhinovirus [105, 129, 171] causes common colds that can progress to fatal infections in high-risk patients. The role for this virus in patients with hematological malignancies is unclear. The number of known parechoviruses is growing rapidly, as novel identification methods have led to the discovery of new variants. Parechoviruses were classified in the Enterovirus genus initially, then found to exhibit different biological features, leading to their reclassification in their own genus. Clinically, they cause the same spectrum of disease as enteroviruses.

The rodent parechovirus known as Ljungan virus is believed to be associated with greater disease severity [1, 6, 20–22, 55, 68, 90, 96, 107, 151, 170, 199, 209, 212, 223, 230, 231, 234, 240, 241]. As with enteroviruses, parechoviruses deserve careful attention in high-risk patients.

### 22.7 Reemerging Viruses

#### 22.7.1 Respiratory Syncytial Virus

The RSV has been known for decades and is not believed to be an emerging pathogen. However, recent investigations have demonstrated clearly that RSV infection is underestimated in the elderly and in patients with other malignancies, where it may cause severe to fatal pneumonia [174, 182, 184, 185, 196, 197, 215, 222]. This increasing incidence in some patient groups may define the RSV as a reemerging pathogen, although it is ascribable to the use, for the first time, of molecular RSV diagnostic methods in vulnerable patient groups. In all likelihood, the RSV was present in these groups previously but went unrecognized.
RSV accounts for a large number of infections throughout the treatment of patients with acute lymphoblastic leukemia. In one study, about 57% of patients were positive for RSV at some point in time [102]. RSV is also of clinical significance following allogeneic bone marrow transplantation and has been found in a substantial proportion of patients with lung infections [64, 133]. Furthermore, RSV was responsible for 55% of fatal pneumonia cases in adult immunocompromised patients treated for lymphoma and leukemia in a retrospective study and was a major cause of viral pneumonia in several cohorts of patients with these hematological malignancies [57, 78, 81, 82, 164, 201, 228].

In patients with hematological malignancies, and most notably in hematopoietic stem cell recipients, RSV infection is fatal in up to 80% of cases [89]. In these patients, ribavirin, immunoglobulins, and the RSV-specific humanized monoclonal antibody palivizumab may be used as specific therapy and/or prophylaxis [18, 32, 36, 38, 60, 69, 70, 75, 80, 83, 104, 110, 138, 139, 145, 159, 181, 211, 224, 225]. However, evidence supporting the use of these treatments remains weak at this time.

### 22.7.2 Parainfluenza Viruses

Clinically, parainfluenza viruses 1–4 cannot be differentiated from RSV or hMPV infection. As they infect the same groups of patients and cause identical symptoms, they require the same attention as other pathogens. They can also be classified among reemerging viruses, as screening was recently introduced. Parainfluenza viruses should be considered in the differential diagnosis of respiratory infection and distinguished from emerging pathogens [98, 154].

### 22.7.3 Influenza Viruses

Influenza viruses are not emerging viruses, as in theory all potential variants and reassortants are identified based on well-known data on the mode of replication and influenza-associated biological phenomena such as antigen shift. Nevertheless, perhaps due to concern that a lethal variant similar to the Spanish flu may return, or due to the awarding of research grants based on this fear, any “novel” influenza virus variant is estimated to have pandemic potential and is therefore classified as an emerging pathogen (and as an opportunity for the media to generate widespread fear of general social disorganization and massive mortality). The most recent virus classified as an emerging influenza virus was the Mexican H1N1 strain identified in 2009.

Recent developments in the swine-originated H1N1 pandemic indicate that the main target is not the elderly population but, instead, younger adults (www.who.org [153, 180]). The immunosenescence concept suggested that older people would be at greatest risk. The predominant involvement of younger individuals suggests a role for unknown factors that contribute to clinical disease. Alternatively, aging might exert a protective effect. However, it must be hoped that the current wave of H1N1 influenza is not a relatively harmless prelude to a second severe outbreak later in the flu season.

As with any influenza variant, the H1N1 strain warrants close attention in high-risk patients. All influenza variants can cause severe pneumonia in patients with hematological malignancies.

### 22.7.4 Adenoviruses

Adenoviruses are small naked DNA viruses that occur worldwide and mainly infect children between 0.5 and 5 years of age. The clinical spectrum ranges from mild to severe respiratory diseases to epidemic keratoconjunctivitis (“pink eye”), tonsillopharyngitis, and gastroenteric disorders (vomiting, diarrhea). Adenoviruses occur in over 50 serotypes, affecting all age groups and causing diseases that are usually self-limiting within 14 days or asymptomatic [46, 62, 71, 92, 130, 131, 135]. Importantly, adenoviruses may persist in the infected host [46, 62, 71, 92, 130, 131, 135] and may undergo reactivation in immunosuppressed patients, including those with hematological malignancies. Adenoviruses play a major role in solid-organ transplant recipients but occur less often in stem cell recipients [46, 62, 71, 92, 130, 131, 135], However, novel and more aggressive adenovirus strains may meet the definition for emerging pathogens and may play a future role in patients with hematological
malignancies. Consequently, adenoviruses deserve attention. More specifically, shedding may be prolonged in high-risk patients, patient isolation may be required, and no antiviral therapy for adenoviruses is available so far [46, 62, 71, 92, 130, 131, 135].

References

1. Abed Y, Boivin G (2005) Molecular characterization of a Canadian human parechovirus (HPeV)-3 isolate and its relationship to other HPeVs. J Med Virol 77:566–570
2. Abed Y, Wang D, Boivin G (2007) WU polyomavirus in children, Canada. Emerg Infect Dis 13:1939–1941
3. Abedi Kiasari B, Vallely PJ, Corless CE, Al-Hammadi M, Klapper PE (2008) Age-related pattern of KI and WU polyomavirus infection. J Clin Virol 43:123–125
4. Albuquerque MC, Pena GP, Varella RB, Gallucci G, Erdman D, Santos N (2009) Novel respiratory virus infections in children. Emerg Infect Dis 15:806–808
5. Albuquerque MC, Rocha LN, Benati FJ, Soares CC, Maranhao AG, Ramirez ML, Erdman D, Santos N (2007) Human bocavirus infection in children with gastroenteritis, Brazil. Emerg Infect Dis 13:1756–1758
6. Alho A, Marttila J, Ionen J, Hyypia T (2003) Diagnostic potential of parechovirus capsid proteins. J Clin Microbiol 41:2294–2299
7. Allander T, Andreason K, Gupta S, Bjerkner A, Bogdanovic G, Persson MA, Dalianis T, Ramqvist T, Andersson B (2007) Identification of a third human polyomavirus. J Virol 81:4130–4136
8. Allander T, Jartti T, Gupta S, Niesters HG, Lehtinen P, Osterback R, Vuorinen T, Waris M, Bjerkner A, Tiveljung-Lindell A, van den Hoogen BG, Hyypia T, Ruuskanen O (2007) Human bocavirus and acute wheezing in children. Clin Infect Dis 44:904–910
9. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B (2005) Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 102:12891–12896
10. Arden KE, McErlean P, Nissen MD, Sloots TP, Mackay IM (2006) Frequent detection of human rhinoviruses, parainfluenzaviruses, coronaviruses, and bocavirus during acute respiratory tract infections. J Med Virol 78:1232–1240
11. Arden KE, Nissen MD, Sloots TP, Mackay IM (2005) New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia. J Med Virol 75:455–462
12. Arthur JL, Higgins GD, Davidson GP, Givney RC, Ratcliff RM (2009) A novel bocavirus associated with gastro-enteritis in Australian children. PLoS Pathog 5:e1000391
13. Babakir-Mina M, Ciccozzi M, Dimonte S, Farchi F, Valdarchi C, Rezza G, Perno CF, Ciotti M (2008) Identification of the novel KI polyomavirus in the respiratory tract of an Italian patient. J Med Virol 80:2012–2014
14. Baker SC, Shimizu C, Shike H, Garcia F, van der Hoek L, Kuijper TW, Reed SL, Rowley AH, Shulman ST, Talbot HK, Williams JV, Burns JC (2006) Human coronavirus-NL63 infection is not associated with acute Kawasaki disease. Adv Exp Med Biol 581:523–526
15. Bastien N, Anderson K, Hart L, Van Caeseele P, Brandt K, Milley D, Hatchette T, Weiss EC, Li Y (2005) Human coronavirus NL63 infection in Canada. J Infect Dis 191:503–506
16. Bastien N, Brandt K, Dust K, Ward D, Li Y (2006) Human Bocavirus infection, Canada. Emerg Infect Dis 12:848–850
17. Bastien N, Chui N, Robinson JL, Lee BE, Dust K, Hart L, Li Y (2007) Detection of human bocavirus in Canadian children in a 1-year study. J Clin Microbiol 45:610–613
18. Bauman J, Eggleston M, Oquist N, Malinoski F (2007) Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab. South Med J 100:669–676
19. Beder LB, Hotomi M, Ogami M, Yamauchi K, Shimada J, Billal DS, Ishiguro N, Yamanaka N (2009) Clinical and microbiological impact of human bocavirus on children with acute otitis media. Eur J Pediatr 166:1365–1372
20. Benschop KS, Schinkel J, Luken ME, van den Broek PJ, Beermsa MF, Menelik N, van Eijk HW, Zaaijer HL, VandenBroucke-Grauls CM, Beld MG, Wolthers KC (2006) Fourth human parechovirus serotype. Emerg Infect Dis 12:1572–1575
21. Benschop KS, Schinkel J, Minnaar RP, Pajkrt D, Spanjерberg L, Kraakman HC, Berkbout B, Zaaijer HL, Beld MG, Wolthers KC (2006) Human parechovirus infections in Dutch children and the association between serotype and disease severity. Clin Infect Dis 42:204–210
22. Benschop K, Thomas X, Serpenti C, Molenkamp R, Wolthers K (2008) High prevalence of human Parechovirus (HPeV) genotypes in the Amsterdam region and identification of specific HPeV variants by direct genotyping of stool samples. J Clin Microbiol 46:3965–3970
23. Bialasiewicz S, Whiley DM, Lambert SB, Jacob K, Bletchley C, Wang D, Nissen MD, Sloots TP (2008) Presence of the newly discovered human polyomaviruses KI and WU in Australian patients with acute respiratory tract infection. J Clin Virol 41:63–68
24. Bialasiewicz S, Whiley DM, Lambert SB, Wang D, Nissen MD, Sloots TP (2007) A newly reported human polyomavirus, KI virus, is present in the respiratory tract of Australian children. J Clin Virol 40:15–18
25. Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, Ramaswamy M, Look DC, Barik S (2007) Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth. J Virol 81:1786–1795
26. Bizri AR, Musharafieh UM (2003) SARS: the flying death. J Méd Liban 51:148–154
27. Bohmer A, Schildgen V, Lusebrink J, Ziegler S, Tillmann RL, Kleines M, Schildgen O (2009) Novel application for isothermal nucleic acid sequence-based amplification (NASBA). J Virol Methods 158:199–201
28. Bonney D, Razali H, Turner A, Will A (2009) Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol 145:667–669
29. Booth CM, Stewart TE (2005) Severe acute respiratory syndrome and critical care medicine: the Toronto experience. Crit Care Med 33:S53–S60

30. Bruckova M, McIntosh K, Kapikian AZ, Chanock RM (1970) The adaptation of two human coronavirus strains (OC38 and OC43) to growth in cell monolayers. Proc Soc Exp Biol Med 135:431–435

31. Calvo C, Garcia-Garcia ML, Blanco C, Santos MJ, Pozo F, Perez-Brena P, Casas I (2008) Human bocavirus infection in a neonatal intensive care unit. J Infect 57:269–271

32. Carbonell-Estrany X, Lazaro y de Mercado P (2009) Health economics and RSV. Paediatr Respir Rev 10(Suppl 1): 12–13

33. Catalano-Pons C, Bue M, Laude H, Cattan F, Moulin F, Menager C, Cosnes-Lambe C, Chalumeau M, Giraud C, Meritet JF, Rozenberg F, Lebon P, Gendrel D (2007) Human bocavirus infection in hospitalized children during winter. Pediatr Infect Dis J 26:959–960

34. Cavallerio JT, Monto AS (2009) Community-wide outbreak of infection with a 229E-like coronavirus in Tecumseh, Michigan. J Infect Dis 122:272–279

35. Chan-Yeung M (2004) Severe acute respiratory syndrome (SARS) and healthcare workers. Int J Occup Environ Health 10:421–427

36. Chavez-Bueno S, Mejias A, Merriman RA, Ahmad N, Jafari HS, Ramilo O (2007) Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 26:1089–1093

37. Chieochansin T, Samransamruajkit R, Chutinimitkul S, Payungporn S, Hiranras T, Theamboonlers A, Poovorawan Y (2008) Human bocavirus (HBoV) in Thailand: clinical manifestations in a hospitalized pediatric patient and molecular virus characterization. J Infect 56:137–142

38. Chirico G, Ravasio R, Sbarigia U (2009) Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Riv Ital Pediatr 35:4

39. Chow LT, Broker TR (1994) Papillomavirus DNA replication. Intervirology 37:150–158

40. Chow BD, Huang YT, Esper FP (2008) Evidence of human bocavirus circulating in children and adults, Cleveland, Ohio. J Clin Virol 43:302–306

41. Christensen A, Nordbo SA, Krokstad S, Rognlien AG, Dollner H (2008) Human bocavirus commonly involved in multiple viral airway infections. J Clin Virol 41:34–37

42. Chung JY, Han TH, Kim CK, Kim SW (2006) Bocavirus infection in hospitalized children, South Korea. Emerg Infect Dis 12:1254–1256

43. Chung JY, Han TH, Kim JS, Kim SW, Park CG, Hwang ES (2008) Th1 and Th2 cytokine levels in nasopharyngeal aspirates from children with human bocavirus bronchiolitis. J Clin Virol 43:223–225

44. Costa C, Bergallo M, Cavallo R (2009) Detection of Human Bocavirus in bronchoalveolar lavage from Italian adult patients. J Clin Virol 45:81–82

45. Dare R, Sanghavi S, Bullotta A, Keightley MC, George KS, Wadowsky RM, Paterson DL, McCurry KR, Reinhart TA, Hussein S, Rinaldo CR (2007) Diagnosis of human metapneumovirus infection in immunosuppressed lung transplant recipients and children evaluated for pertussis. J Clin Microbiol 45:548–552

46. Darr S, Madisch I, Hofmayer S, Rehren F, Heim A (2009) Phylogeny and primary structure analysis of fiber shafts of all human adenovirus types for rational design of adenoviral gene therapy vectors. J Gen Virol 90:2849–2854

47. de Graaf M, Osterhaus AD, Fouchier RA, Holmes EC (2008) Evolutionary dynamics of human and avian metapneumoviruses. J Gen Virol 89:2933–2942

48. de Graaf M, Schrauwen EJ, Herfst S, van Amerongen G, Osterhaus AD, Fouchier RA (2009) Fusion protein is the main determinant of metapneumovirus host tropism. J Gen Virol 90:1408–1416

49. de Vries JJ, Bredius RG, van Rheeinen PF, Smiers FJ, Scholvinck EH, Vossen AC, Claas EC, Niesters HG (2009) Human bocavirus in an immunocompromised child presenting with severe diarrhea. J Clin Microbiol 47:1241–1243

50. Debiaggi M, Canducci F, Sampaolo M, Marinozzi MC, Parea M, Terulla C, Colombo AA, Alessandrino EP, Braggot LZ, Arghiuttu M, Goglio A, Migliavacca R, Romero E, Clementi M (2006) Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis 194:474–478

51. Deiss V, Tsatskin JD, Weitz M, Siegl G (1990) Cloning of the human parvovirus B19 genome and structural analysis of its palindromic termini. Virology 175:247–254

52. Dijkman R, Koekkoek SM, Molenkamp R, Schildgen O, van der Hoek L (2009) Human bocavirus can be cultured in differentiated human airway epithelial cells. J Virol 83:7739–7748

53. Dijkman R, van der Hoek L (2009) Human coronaviruses 229E and NL63: close yet still so far. J Formos Med Assoc 108:270–279

54. Ditt V, Viazov S, Tillmann R, Schildgen V, Schildgen O (2008) Genotyping of human bocavirus using a restriction length polymorphism. Virus Genes 36:67–69

55. Drexlter JF, Grywna K, Stocker A, Almeida PS, Medrado-Ribeiro TC, Eschbach-Bludau M, Petersen N, Da Costa-Ribeiro H Jr, Drosten C (2009) Novel human parvovirus from Brazil. Emerg Infect Dis 15:310–313

56. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cintal J, Eickmann M, Escirou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:1967–1976

57. Ebertt JO, Limper AH (2005) Respiratory syncytial virus pneumonia in immunocompromised adults: clinical features and outcome. Respiration 72:263–269

58. Ebihara T, Endo R, Ma X, Ishiguro N, Kikuta H (2005) Detection of human coronavirus NL63 in young children. J Med Virol 77:295–300

59. Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JB, Buick R, Stevenson NJ, Touzelet O, Gadina M, Power UF, Johnston JA (2007) Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ubiquitin ligase. J Virol 81:3428–3436

60. Emerick K, Cunningham M, Hartnick C (2006) The potential impact of palivizumab on pediatric airway reconstruction. Am J Otalaryngol 27:9–12
61. Endo R, Ishiguro N, Kikuta H, Teramoto S, Shirkoohi R, Ma X, Ebihara T, Ishiko H, Ariga T (2007) Seroepidemiology of human bocavirus in Hokkaido prefecture, Japan. J Clin Microbiol 45:3218–3223
62. Engelmann I, Madisch I, Pommer H, Heim A (2006) An outbreak of epidemic keratoconjunctivitis caused by a new intermediate adenovirus 22/H8 identified by molecular typing. Clin Infect Dis 43:e64–e66
63. Englund JA, Boechk M, Kyupers J, Nichols WG, Hackman RC, Morrow RA, Fredricks DN, Corey L (2006) Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 144:344–349
64. Escribano DL, Gasparretto EL, Marchiori E, Rocha Gde M, Inoue C, Pasquinii R, Muller NL (2005) Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients. AJR Am J Roentgenol 185:608–615
65. Esper F, Weibel C, Ferguson D, Landry ML, Kahn JS (2005) Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis 191:492–498
66. Esposito S, Bosis S, Niesters HG, Tremolati E, Sabatini C, Porta A, Fossali E, Osterhaus AD, Principi N (2008) Impact of human bocavirus on children and their families. J Clin Microbiol 46:1337–1342
67. Estola T (1970) Coronaviruses, a new group of animal RNA viruses. Avian Dis 14:330–336
68. Faria NR, de Vries M, van Hemert FJ, Benschop K, van der Meer JW (2006) Identification of adenovirus type 2 correlates with disease manifestations and organ failure during disseminated infection. J Med Virol 80:294–297
69. Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, Osterhaus AD (2004) A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci USA 101:6122–6126
70. Foulke JH, Lyle R, Fentiman IS, Page P, Gaffen S, Winer P (2001) An outbreak of respiratory syncytial virus in young adults. V. Coronavirus 229E infections during six years of surveillance. Am J Epidemiol 159:151–159.
71. Forbes M (2008) Strategies for preventing respiratory syncytial virus. Am J Health Syst Pharm 65:S13–S19
72. Forstmeier D, Henke-Gendo C, Brock G, Wildner O, Heim A (2008) Quantitative temporal and spatial distribution of adenovirus type 2 correlates with disease manifestation and organ failure during disseminated infection. J Med Virol 80:294–297
73. Fouquier RA, Hartwig NG, Bestebroer TM, Niemeyer B, de Jong JC, Simon JH, Osterhaus AD (2004) A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci USA 101:6122–6126
74. Fouquey P, Duree O, Kruger N, Moles JP, Guillot B, Segondy M (2009) Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol 162:59–63
75. Fouquey P, Lejeune P, Aloue O, Rodiere M, Segondy M (2006) Human bocavirus in French children. Emerg Infect Dis 12:1251–1253
76. Furlonge V, Duree O, Kluger N, Moles JP, Guillot B, Segondy M (2009) Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol 162:59–63
77. Garcia ML, Calvo C, Pozo F, Perez-Brena P, Vazquez MC, Casas I, et al. (2009) Detection of human bocavirus in ill and healthy Spanish children: a 2-year study. Arch Dis Child. 94:249. doi. 10.1136/adc.2007.131045
78. Garcia R, Raad I, Ab-Said D, Bodey G, Champlin R, Tarrand J, Hill LA, Umphrey J, Neumann J, Englund J, Whimbey E (1997) Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol 18:412–416
79. Gaynor AM, Nissen MD, Whiteley DM, Mackay IM, Lambert SB, Wu G, Brennan DC, Storch GA, Sloots TP, Wang D (2007) Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 3:64
80. Georgescu G, Chemaly RF (2009) Palivizumab: where to from here? Expert Opin Biol Ther 9:139–147
81. Ghosh S, Champlin RE, Enlund J, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, Whimbey E (2000) Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 25:751–755
82. Ghosh S, Champlin RE, Ueno NT, Anderlini P, Rolston K, Raad I, Kontoyiannis D, Jacobson K, Luna M, Tarrand J, Whimbey E (2001) Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant 28:271–275
83. Godard NL, Cooke MC, Gupta RK, Nguyen-Van-Tam JS (2007) Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. Epidemiol Infect 135:159–162
84. Hambre D, Beem M (1972) Virologic studies of acute respiratory disease in young adults. V. Coronavirus 229E infections during six years of surveillance. Am J Epidemiol 96:94–106
85. Hamelin ME, Prince GA, Boivin G (2006) Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother 50:774–777
86. Hamza IA, Jurzick L, Wilhelm M, Uberla K (2009) Detection and quantification of human bocavirus in river water. J Gen Virol 90:2634–2637
87. Han TH, Chung JY, Kim SW, Hwang ES, Raad I, Kontoyiannis D, Jacobson K, Luna M, Tarrand J, Whimbey E (2001) Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant 25:751–755
88. Hamza IA, Jurzick L, Wilhelm M, Uberla K (2009) Detection and quantification of human bocavirus in river water. J Gen Virol 90:2634–2637
89. Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, Benson A, Meyers JD (1992) An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 165:987–993
90. Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, Benson A, Meyers JD (1992) An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 165:987–993
91. Harvila H, Robertson I, McWilliam Leitch EC, Benschop K, Wolthers KC, Templeton K, Simmons P (2008) Epidemiology and clinical associations of human parechovirus respiratory infections. J Clin Microbiol 46:3446–3453
against human bocavirus viral protein 2 viruslike particles in healthy adults. J Infect Dis 198:1677–1684

122. Ling Z, Tran KC, Teng MN (2009) The human respiratory syncytial virus nonstructural NS2 protein antagonizes the activation of interferon-\([\beta]\) transcription by interacting with RIG-I. J Virol 83:3734–3742

123. Lo MS, Brazas RM, Holtzman MJ (2005) Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol 79:9315–9319

124. Longtin J, Bastien M, Gilca R, Leblanc E, de Serres G, Bergeron MG, Boivin G (2008) Human bocavirus infections in hospitalized children and adults. Emerg Infect Dis 14:217–221

125. Louie JK, Schnurr DP, Pan CY, Kiang D, Carter C, Tougaw S, Ventura J, Norman A, Belmusto V, Rosenberg J, Trochet G (2007) A summer outbreak of human metapneumovirus infection in a long-term-care facility. J Infect Dis 196:705–708

126. Lu X, Gooding LR, Erdman DD (2008) Human bocavirus in tonsillar lymphocytes. Emerg Infect Dis 14:1332–1334

127. Ma X, Endo R, Ishiguro N, Ebihara T, Ishiko H, Ariga T, Kikuta H (2006) Detection of human bocavirus in Japanese children with lower respiratory tract infections. J Clin Microbiol 44:1132–1134

128. Mackay IM (2007) Human bocavirus: multisystem detection raises questions about infection. J Infect Dis 196:968–970

129. Mackay IM, Lambert SB, McErlean PK, Faux CE, Arden KE, Nissen MD, Sloots TP (2008) Prior evidence of putative novel rhinovirus species, Australia. Emerg Infect Dis 14:1823–1824

130. Madisch I, Heim A (2007) Extent of circulation of incorrectly labeled adenovirus 50 and 51 prototype preparations. J Clin Microbiol 45:2092

131. Madisch I, Wolfel R, Harste G, Pommer H, Heim A (2006) Molecular identification of adenovirus sequences: a rapid scheme for early typing of human adenoviruses in diagnostic samples of immunocompetent and immunodeficient patients. J Med Virol 78:1210–1217

132. Maggi F, Andreoli E, Pifferi M, Meschi S, Rocchi J, Andreoli E, Pifferi M, Meschi S, Rocchi J, Maggi F, Andreoli E, Pifferi M, Meschi S, Rocchi J (2007) Human bocavirus in Italian patients with respiratory diseases. J Clin Microbiol 45:321–325

133. Marchiori E, Escuissato DL, Considera DP, Franquet T (2009) “Crazy-paving” patterns on high-resolution CT scans in patients with pulmonary complications after hematopoietic stem cell transplantation. Korean J Radiol 10:21–24

134. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattri J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsoh B, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernandez L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL (2003) The Genome sequence of the SARS-associated coronavirus. Science 300:1399–1404

135. Mattner F, Sykora KW, Meissner B, Heim A (2008) An adenovirus type F41 outbreak in a pediatric bone marrow transplant unit: analysis of clinical impact and preventive strategies. Pediatr Infect Dis J 27:419–424

136. McIntosh K (2006) Human bocavirus: developing evidence for pathogenicity. J Infect Dis 194:1197–1199

137. McIntosh K, Kapikian AZ, Turner HC, Hartley JW, Parrott RH, Chanock RM (1970) Seroepidemiologic studies of coronavirus infection in adults and children. Am J Epidemiol 91:585–592

138. Meberg A, Bruu AL (2006) Respiratory syncytial virus infections in congenital heart defects–hospitalizations and costs. Acta Paediatr 95:404–406

139. Michaelis MG, Fonseca Aten M, Green M, Charsha-May D, Friedman B, Seikaly M, Sanchez PJ (2009) Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant 13:451–456

140. Minoes C, Selleri M, Zaniratti MS, Cappiello G, Sano A, Schifano E, Lauria FN, Gualano G, Puro V, Campanini G, Gerna G, Capobianchi MR (2008) Phylogenetic analysis of human coronavirus NL63 circulating in Italy. J Clin Virol 43:114–119

141. Miyakaki S, van Hal SJ, Barratt J, Stark D, Marrott D, Harkness J (2009) Absence of human Bocavirus in bronchoalveolar lavage fluid of lung transplant patients. J Clin Virol 44:179–180

142. Miyazaki K, Tsunoda A, Kumasaka M, Ishida N (1971) Presence of neutralizing antibody against the 229E strain of coronavirus in the sera of residents of Sendai. Jpn J Infect Dis 12:183–184

143. Monteny M, Niesters HG, Mol LA, Berger MY (2007) Human bocavirus in febrile children, The Netherlands. Emerg Infect Dis 13:180–182

144. Moore EC, Barber J, Tripp RA (2008) Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol J 5:116

145. Morris SK, Dzolganovski B, Beyene J, Sung L (2009) A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis 9:106

146. Muller A, Klinkenberg D, Vehreschild J, Cornely O, Kaiser R, Muller A, Klinkenberg D, Vehreschild J, Cornely O, Kaiser R, Muller A, Klinkenberg D, Vehreschild J, Cornely O, Kaiser R (2009) Fatal pneumonia associated with human metapneumovirus (HMPV) in a patient with myeloid leukemia and adenocarcinoma in the lung. Eur J Med Res 12:183–184

147. Muller A, Klinkenberg D, Vehreschild J, Cornely O, Kaiser R, Seifert H, Viazov S, Tillmann RL, Franzen C, Simon A, Schildgen O (2009) Low prevalence of human metapneumovirus and human bocavirus in adult immunocompromised high risk patients suspected to suffer from Pneumocystis pneumonia. J Infect Dis 58:227–231

148. Munir S, Le Nouen C, Luongo C, Buchholz UJ, Collins PL, Bukreyev A (2008) Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol 82:8780–8796
149. Naghipour M, Cuevas LE, Bakhshinejad T, Dove W, Hart CA (2007) Human bocavirus in Iranian children with acute respiratory infections. J Med Virol 79:539–543

150. Neske F, Blessing K, Ulrich F, Prottel A, Wolfgang Kreth H, Weissbrich B (2008) WU polyomavirus infection in children, Germany. Emerg Infect Dis 14:680–681

151. Niklasson B, Samsioe A, Papadogiannakis N, Gustafsson S, Kilt W (2009) Zoonotic Ljungan virus associated with central nervous system malformations in terminated pregnancy. Birth Defects Res A Clin Mol Teratol 85:542–545

152. Norja P, Ubillos I, Templeton K, Simmonds P (2007) No evidence for an association between infections with WU and KI polyomaviruses and respiratory disease. J Clin Virol 40:307–311

153. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM (2009) Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N Engl J Med 360:2605–2615

154. Osterhaus AD (2008) New respiratory viruses of humans. Pediatr Infect Dis J 27:S71–S74

155. Payungporn S, Chieochansin T, Thongmee C, Samran-samruajkit R, Theamboolers A, Poovorawan Y (2008) Prevalence and molecular characterization of WU/KI polyomaviruses isolated from pediatric patients with respiratory infection, Thailand. Virus Res 135:230–236

156. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM (2009) Human bocavirus infection in hospitalized children in Italy. J Clin Virol 43:109–115

157. Pene F, Merlat A, Vabret A, Rozenberg F, Buzyn A, Dreyfus F, Cariou A, Freymuth F, Lebon P (2003) Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis 37:929–932

158. Pierangeli A, Scagnolari C, Trombetti S, Grossi R, Battaglia M, Moretti C, Midulla F, Antonelli G (2008) Human bocavirus infection in hospitalized children in Italy. Influenza Other Respir Viruses 2:175–179

159. Pignotti MS, Catarzi S, Donzelli G (2006) A 4-year survey on palivizumab respiratory syncytial virus (RSV)- prophylaxis: how can compliance be improved? J Matern Fetal Neonatal Med 19:221–224

160. Pozo F, Garcia-Garcia ML, Calvo C, Cuesta I, Perez-Brena P, Casas I (2007) High incidence of human bocavirus infection in children in Spain. J Clin Virol 40:224–228

161. Pyre K, Dijkman R, Deng L, Jebbink MF, Ross HA, Berkhout B, van der Hoek L (2006) Novel species of human rhinoviruses in acute otitis media. Pediatr Infect Dis J 25:553–556

162. Qu XW, Duan ZJ, Qi ZY, Xie ZP, Gao HC, Liu WP, Huang CP, Peng FW, Zheng LS, Hou YD (2007) Human bocavirus infection, People’s Republic of China. Emerg Infect Dis 13:165–168

163. Qu XW, Liu WP, Qi ZY, Duan ZJ, Zheng LS, Kuang ZZ, Zhang WJ, Hou YD (2008) Phospholipase A2-like activity of human bocavirus VP1 unique region. Biochem Biophys Res Commun 365:158–163

164. Raad I, Abbas J, Whimbey E (1997) Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med 102:48–52, discussion 53-4

165. Raza K, Ismailjee SB, Crespo M, Studer SM, Sanghavi S, Paterson DL, Kwak EJ, Rinaldo CR Jr, Pilewski JM, McCurry KR, Husain S (2007) Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 26:862–864

166. Redshaw N, Wood C, Rich F, Grimwood K, Kirman JR (2007) Human bocavirus in infants, New Zealand. Emerg Infect Dis 13:1797–1799

167. Regamey N, Frey U, Defernez C, Latzin P, Kaiser L (2007) Isolation of human bocavirus from Swiss infants with respiratory infections. Pediatr Infect Dis J 26:177–179

168. Revie D, Tseng BY, Graftstrom RH, Goulian M (1979) Covalent association of protein with replicative form DNA of parvovirus H-1. Proc Natl Acad Sci USA 76:5539–5543

169. Rockville Merkel Cell Carcinoma Group (2009) Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol 27:4021–4026

170. Samsioe A, Papadogiannakis N, Hultman T, Sjoholm A, Kilt W, Niklasson B (2009) Ljungan virus present in intrauterine fetal death diagnosed by both immunohistochemistry and PCR. Birth Defects Res A Clin Mol Teratol 85:227–229

171. Savolainen-Kopra C, Blomqvist S, Kilpi T, Roivainen M, Hovi T (2009) Novel species of human rhinoviruses in acute otitis media. Pediatr Infect Dis J 28:59–61

172. Schenk T, Huck B, Forster J, Berner R, Neumann-Haefelin D, Falcone V (2007) Human bocavirus DNA detected by quantitative real-time PCR in two children hospitalized for lower respiratory tract infection. Eur J Clin Microbiol Infect Dis 26:147–149

173. Schenk T, Strahm B, Kontny U, Hufnagel M, Neumann-Haefelin D, Falcone V (2007) Disseminated bocavirus infection after stem cell transplant. Emerg Infect Dis 13:1425–1427

174. Schildgen O (2009) The lack of protective immunity against RSV in the Elderly. Epidemiol Infect 137:1687–1690

175. Schildgen O, Geikowski T, Glatzel T, Simon A, Wilkesmann S, Muller A, Roggendorf M, Viazov S, Matz B (2004) New variant of human metapneumovirus (hMPV) associated with an acute and severe exacerbation of asthma bronchiale. J Clin Virol 31:283–288

176. Schildgen O, Muller A, Allander T, Mackay IM, Volz S, Kupfer B, Simon A (2008) Human bocavirus: passenger or pathogen in acute respiratory tract infections? Clin Microbiol Rev 21:291–304

177. Schildgen O, Muller A, Simon A (2007) Human bocavirus and gastroenteritis. Emerg Infect Dis 13:1620–1621

178. Schildgen O, Wilkesmann A, Simon A (2006) Wheezing in children with human metapneumovirus infection. J Allergy Clin Immunol 117:223, author reply 223-4

179. Shan TL, Zhang W, Guo W, Cui L, Yuan CL, Dai XQ, Shen Q, Yang ZB, Zhu JG, Hua XG (2009) The first detection of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 26:862–864

180. Shinde V et al (2009) Triple-Reassortant Swine Influenza A (H1) in humans in United States, 2005–2009. NEJM 360:2616–2625
181. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL (2007) Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 151:34–42, 42 e1

182. Simon A, Ammann RA, Wilkesmann A, Eis-Hubinger AM, Schildgen O, Weimann E, Peltner HU, Seiffert P, Suss-Grafeco A, Groothuis JR, Liese J, Pallacks R, Muller A (2007) Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr 166:1273–1283

183. Simon A, Gronke P, Kupfer B, Kaiser R, Plun G, Tillmann RL, Muller A, Schildgen O (2007) Detection of bocavirus DNA in nasopharyngeal aspirates of a child with bronchiolitis. J Infect 54:e125–e127

184. Simon A, Khurana K, Wilkesmann A, Muller A, Engelhart S, Exner M, Schildgen O, Eis-Hubinger AM, Groothuis JR, Bode U (2006) Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control. Int J Hyg Environ Health 209:317–324

185. Simon A, Muller A, Khurana K, Engelhart S, Exner M, Schildgen O, Eis-Hubinger AM, Kamin W, Schaible T, Wadas K, Ammann RA, Wilkesmann A (2008) Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection – results from a prospective multicenter German surveillance study. Int J Hyg Environ Health 211:241–250

186. Skowronski DM, Astell C, Brunham RC, Low DE, Petric M, Roper RL, Talbot PJ, Tam T, Babiuk L (2005) Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 56:357–381

187. Sloots TP, McErlean P, Speicher DJ, Arden KE, Nissen S, Nishimura H (2005) Detection of human coronavirus NL63 in children in Japan. Pediatr Infect Dis J 24:365–373

188. Smuts H (2008) Human coronavirus NL63 infections in infants hospitalised with acute respiratory tract infections in South Africa. Influenza Other Respir Viruses 2:135–138

189. Smuts H, Hardie D (2006) Human bocavirus in hospitalized children, South Africa. Emerg Infect Dis 12:1457–1458

190. Smuts H, Workman L, Zar HJ (2008) Role of human metapneumovirus, human coronavirus NL63 and human bocavirus in infants and young children with acute wheezing. J Med Virol 80:906–912

191. Spann KM, Tran KC, Collins PL (2005) Effects of non-structural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol 79:5353–5362

192. Sumino KC, Agapol E, Pierce RA, Trulock EP, Pfeifer JD, Ritter JH, Gaudreault-Keener M, Storch GA, Holtzman MJ (2005) Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment. J Infect Dis 192:1052–1060

193. Suzuki A, Okamoto M, Ohmi A, Watanabe O, Miyabayashi S, Nishimura H (2005) Detection of human coronavirus-NL63 in children in Japan. Pediatr Infect Dis J 24:645–646

194. Szomor KN, Kapusinszky B, Rigo Z, Kis Z, Rozsa M, Farkas A, Szilagyi A, Berencsi G, Takacs M (2009) Detection of human bocavirus from fecal samples of Hungarian children with acute gastroenteritis. Intervirology 52:17–21

195. Tan BH, Lim EA, Seah SG, Loo LH, Lee NL, Lin RT, Sugrue RJ (2009) The incidence of human bocavirus infection among children admitted to hospital in Singapore. J Med Virol 81:82–89

196. Terrosi C, Di Genova G, Martorelli B, Valentini M, Cusi MG (2009) Humoral immunity to respiratory syncytial virus in young and elderly adults. Epidemiol Infect 137:1684–1686

197. Terrosi C, Di Genova G, Savellini GG, Correale P, Blardi P, Cusi MG (2007) Immunological characterization of respiratory syncytial virus N protein epitopes recognized by human cytotoxic T lymphocytes. Viral Immunol 20:399–406

198. Terrosi C, Fabbiani M, Cellesi C, Cusi MG (2007) Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing. J Clin Virol 40:43–45

199. Tolf C, Gullberg M, Johansson ES, Tesh RB, Andersson B, Lindberg AM (2009) Molecular characterization of a new Ljungan virus (Parechovirus; Picornaviridae) reveals a fourth genotype and indicates ancestral recombination. J Gen Virol 90:843–853

200. Tolou H, Buissyn Y (2007) Human Bocavirus: a new respiratory pathogen? Med Trop 67:13–14

201. Torres HA, Aguillera EA, Mattiuuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, Kantarjian HM, Jiang Y, Safdar A, Raad II, Chemaly RF (2007) Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica 92:1216–1223

202. Vabret A, Mourez T, Dina J, van der Hoek L, Gourarin S, Petitjean J, Brouard J, Freymuth F (2005) Human coronavirus NL63, France. Emerg Infect Dis 11:1225–1229

203. Vallet C, Pons-Catalano C, Mandelcwajg A, Wang A, Raymond J, Lebon P, Gendrel D (2009) Human bocavirus: a cause of severe asthma exacerbation in children. J Pediatr 155:286–288

204. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus AD (2001) A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 7:719–724

205. van den Hoogen BG, Osterhaus DM, Fouchier RA (2004) Clinical impact and diagnosis of human metapneumovirus infection. Pediatr Infect Dis J 23:S25–S32

206. van den Hoogen BG, van Doornum GJ, Fockens JC, Cornelissen JJ, Beyer WE, de Groot R, Osterhaus AD, Fouchier RA (2003) Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis 188:1571–1577

207. van der Hoek L, Pyke K, Jebbink MF, Vermeulen-Oost W, de Jong JC, van der Hoek L, Gourarin S, Petitjean J, Brouard J, Freymuth F. (2007) Human coronavirus NL63, France. Emerg Infect Dis 11:1225–1229

208. van der Hoek L, Sure K, Ihorst G, Stang A, Pyke K, Jebbink MF, Petersen G, Forster J, Berkhout B, Uberla K (2006) Human coronavirus NL63 infection is associated with croup. Adv Exp Med Biol 581:485–491

209. van der Sanden S, Steenbergen GJ, De Bruin E, Vennema H, Swanink C, Koopmans M, van der Avoort H (2008) Prevalence of human bocavirus in infants hospitalised with acute wheezing. Adv Exp Med Biol 581:485–491
human parechovirus in the Netherlands in 2000 to 2007. J Clin Microbiol 46:2884–2889

210. Velayudhan BT, Nagaraja KV, Thachil AJ, Shaw DP, Gray GC, Halvorson DA (2006) Human metapneumovirus in turkey pouls. Emerg Infect Dis 12:1853–1859

211. Venkatesh MP, Weisman LE (2006) Prevention and treatment of respiratory syncytial virus infection in infants: an update. Expert Rev Vaccines 5:261–268

212. Verboon-Maciolek MA, Groenendaal F, Hahn CD, Hellmann J, van Loon AM, Boivin G, de Vries LS (2008) Human parechovirus causes encephalitis with white matter injury in neonates. Ann Neurol 64:266–273

213. Vicente D, Cilla G, Montes M, Perez-Yarza EG, Perez-Trallero E (2007) Human bocavirus, a respiratory and enteric virus. Emerg Infect Dis 13:636–637

214. Villa L, Melon S, Suarez S, Alvarez-Aguelles ME, Gonzalez D, Morilla A, Boga JA, Rodriguez J, de Ona M (2008) Detection of human bocavirus in Asturias, Northern Spain. Eur J Clin Microbiol Infect Dis 27:237–239

215. Voigt E, Tillmann RL, Schewe JC, Molitor E, Schildgen O (2008) ARDS in an HIV-positive patient associated to respiratory syncytial virus. Eur J Med Res 13:131–132

216. Volz S, Schildgen O, Klinkenberg D, Vitt M, Muller A, Tillmann RL, Kupfer B, Bode U, Lentze MJ, Simon A (2007) Prospective study of Human Bocavirus (HBoV) infection in a pediatric university hospital in Germany 2005/2006. J Virol 40:229–235

217. Volz S, Schildgen O, Muller A, Tillmann RL, Eis-Hubinger AM, Kupfer B, Bode U, Lentze ML, Simon A (2007) The human bocavirus: pathogen in airway infections? Dtch Med Wochenschr 132:1529–1533

218. von Linstow ML, Eugen-Olsen J, Koch A, Winther TN, Westh H, Hogh B (2006) Excretion patterns of human metapneumovirus and respiratory syncytial virus among young children. Eur J Med Res 11:329–335

219. von Linstow ML, Hogh M, Hogh B (2008) Clinical and epidemiologic characteristics of human bocavirus in Danish infants: results from a prospective birth cohort study. Pediatr Infect Dis J 27:897–902

220. von Linstow ML, Hogh M, Nordbo SA, Eugen-Olsen J, Koch A, Hogh B (2008) A community study of clinical traits and risk factors for human metapneumovirus and respiratory syncytial virus infection during the first year of life. Eur J Pediatr 167:1125–1133

221. von Linstow ML, Larsen HH, Eugen-Olsen J, Koch A, Nordmann Winther T, Meyer AM, Westh H, Lundgren B, Melbye M, Hogh B (2004) Human metapneumovirus and respiratory syncytial virus in hospitalized danish children with acute respiratory tract infection. Scand J Infect Dis 36:578–584

222. von Renesse A, Schildgen O, Klinkenberg D, Muller A, von Moers A, Simon A (2009) Respiratory syncytial virus infection in children admitted to hospital but ventilated mechanically for other reasons. J Med Virol 81:160–166

223. Wakatsuki K, Kawamoto D, Hiwaki H, Watanabe K, Yoshida H (2008) Identification and characterization of two strains of human parechovirus 4 isolated from two clinical cases in Fukuoka City, Japan. J Clin Microbiol 46:3144–3146

224. Wang D, Cummins C, Bayliss S, Sandercock J, Burlis A (2008) Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 12(3):i–x, 1–86

225. Weisman LE (2009) Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future. Cardiovasc Hematol Agents Med Chem 7:223–233

226. Weissbrich B, Nesse F, Schubert J, Tollmann F, Blath K, Blessing K, Kreth HW (2006) Frequent detection of bocavirus DNA in German children with respiratory tract infections. BMC Infect Dis 6:109

227. Wenzel RP, Bearman G, Edmond MB (2005) Lessons from severe acute respiratory syndrome (SARS): implications for infection control. Arch Med Res 36:610–616

228. Whimbey E, Couch RB, Englund JA, Andreeff M, Goodrich LM, Raad V II, Lewis NM, Luna MA, Baxter B et al (1995) Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 21:376–9

229. Wilkesmann A, Schildgen O, Eis-Hubinger AM, Geikowski T, Glatzel T, Lentze MJ, Bode U, Simon A (2006) Human metapneumovirus infections cause similar symptoms and clinical severity as respiratory syncytial virus infections. Eur J Pediatr 165:467–475

230. Williams CH, Panayiotou M, Girling GD, Peard CI, Oikarinen S, Hyoty H, Stanway G (2009) Evolution and conservation in human parechovirus genomes. J Gen Virol 90:1702–1712

231. Wolthers KC, Benschop KS, Schinkel J, Molenkamp R, Bergevoet RM, Spijkerman IJ, Kraakman HC, Pajkrt D (2008) Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. Clin Infect Dis 47:358–363

232. Woo PC, Lau SK, Chu CM, Chan KH, Tsio HW, Huang Y, Wong BH, Poon RW, Cai JJ, Luk WK, Poon LL, Wong SS, Guan Y, Peiris JS, Yuen KY (2005) Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 79:884–895

233. Woo PC, Lau SK, Huang Y, Tsio HW, Chan KH, Yuen KY (2005) Phylogenetic and recombination analysis of coronavirus HKU1, a novel coronavirus from patients with pneumonia. Arch Virol 150:2299–2311

234. Yamamoto M, Abe K, Kuniyori K, Kuni I, Eto F, KasaMA, YoshioY, Noda M (2009) Epidemic of human parechovirus type 3 in Hiroshima city, Japan in 2008. Jpn J Infect Dis 62:244–245

235. Yu JM, Li DD, Xu ZQ, Cheng WX, Zhang Q, Li HY, Cui SX, Miao J, Yang SH, Fang ZY, Duan ZJ (2008) Human bocavirus infection in children hospitalized with acute gastroenteritis in China. J Clin Virol 42:280–285

236. Zadori ZSJ, Lacoste MC, Li Y, Gariepy S, Raymond P, Bergevoet RM, Spijkerman IJ, Kraakman HC, Pajkrt D (2008) Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children. Clin Infect Dis 47:358–363

237. Zhao LQ, Qian Y, Zhu RN, Deng J, Wang F, Dong HJ, Sun Y, Li Y (2009) Human bocavirus infections are common in Beijing population indicated by sero-antibody prevalence analysis. Chin Med J (Engl) 122:1289–1292
239. Ziegler S, Tillmann RL, Muller A, Simon A, Schildgen V, Schildgen O (2008) No gastroenteric Bocavirus in high risk patients stool samples. J Clin Virol 43:349–350

240. Zoll J, Erkens Hulshof S, Lanke K, Verduyn Lunel F, Melchers WJ, Schoondermark-van de Ven E, Roivainen M, Galama JM, van Kuppeveld FJ (2009) Saffold virus, a human Theiler’s-like cardiovirus, is ubiquitous and causes infection early in life. PLoS Pathog 5:e1000416

241. Zoll J, Galama JM, van Kuppeveld FJ (2009) Identification of potential recombination breakpoints in human parechoviruses. J Virol 83:3379–3383

242. zur Hausen H (2008) Novel human polyomaviruses – re-emergence of a well known virus family as possible human carcinogens. Int J Cancer 123:247–250